Whole-Body [(18)F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687

ACRIN 6687, a multi-center clinical trial evaluating differential response of bone metastases to dasatinib in men with metastatic castration-resistant prostate cancer (mCRPC), used [(18)F]-fluoride (NaF) PET imaging. We extend previous ACRIN 6687 dynamic imaging results by examining NaF whole-body (...

Descripción completa

Detalles Bibliográficos
Autores principales: Muzi, Mark, O’Sullivan, Finbarr, Perk, Timothy G., Muzi, John P., Mankoff, David A., Jeraj, Robert, Duan, Fenghai, Yu, Evan Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167705/
https://www.ncbi.nlm.nih.gov/pubmed/33923126
http://dx.doi.org/10.3390/tomography7020013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167705/
https://www.ncbi.nlm.nih.gov/pubmed/33923126
http://dx.doi.org/10.3390/tomography7020013

Ejemplares similares